Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eye drops aim to tame uveitis without steroids

NCT ID NCT07285070

Disease control Sponsor: Novaliq GmbH Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 29, 2026 · Updated 3 times

Summary

This study tests NOV05, a water-free tacrolimus eye drop, in 20 adults with active non-infectious anterior uveitis. Participants receive either a high or low dose for 6 weeks. The goal is to see if it safely controls inflammation and reduces the need for steroid eye drops.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tacrolimus eye drops
What this could lead to
If successful, this could provide a steroid-sparing option to control eye inflammation in uveitis patients.
What could go wrong
This is a small, early-phase proof-of-concept study with only 20 participants. The treatment may not prove effective or safe enough to advance.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Be ≥18 years of age; * Provide written informed consent; * Be diagnosed with active non-infectious anterior uveitis requiring initiation or increase of topical steroids administration for the management of ocular inflammation; * Have an onset of symptoms within 4 weeks; Exclusion Criteria: * Have severe/serious ocular pathology in the study eye which may preclude study completion or interferes with trial assessment, in the judgement of the clinical Investigator; * Have a history of or a current ocular or periocular malignancy; * Have active intermediate or posterior uveitis in the study eye or another documented posterior segment inflammation; * A confirmed or highly suspicious infectious uveitis eg, CMV, Herpes simplex, Herpes zoster, syphilis, tuberculosis, lyme disease; * Have a known allergy or sensitivity to the IMP tacrolimus or semifluorinated alkanes (SFA); * Be a woman who is pregnant, nursing, or planning a pregnancy; * Have a condition or be in a situation (e.g. language barrier, non-cooperative, history of substance abuse) which the Investigator considers that it may put the patient at significant risk, may confound the trial results, or may significantly interfere with the patient's participation in the trial;

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-infectious anterior uveitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-infectious anterior uveitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-infectious anterior uveitis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    6 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Bascom Palmer Eye Institute

    RECRUITING

    Miami, Florida, 33136, United States

  • Horizon Eye & Lasik Center

    RECRUITING

    Phoenix, Arizona, 85004, United States

  • Massachusetts Eye Research and Surgery Institution

    RECRUITING

    Waltham, Massachusetts, 02451, United States

  • Metropolitan Eye Research and Surgery Institute

    RECRUITING

    Palisades Park, New Jersey, 07650, United States

  • Valley Retina Institute, P.A.

    RECRUITING

    McAllen, Texas, 78503, United States

  • Virginia Eye Consultants

    RECRUITING

    Norfolk, Virginia, 23502, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.